Drug intelligence / Profile preview

zhilong huoxue tongyu capsule

Development stage
Phase 2
Lead developer
Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University
Administration
Oral
01

Overview

Zhilong Huoxue Tongyu Capsule is a traditional Chinese medicine (TCM) oral capsule formulation used primarily for promoting blood circulation, removing blood stasis, and unblocking meridians. It is indicated for the recovery period of ischemic stroke (arteriosclerotic cerebral infarction) in patients diagnosed with Qi deficiency and blood stasis syndrome according to TCM principles. Clinical symptoms include hemiplegia, numbness on one side of the body, facial paralysis, and speech difficulties[1][7]. The formula contains multiple herbal ingredients such as Astragalus membranaceus (Huangqi), Whitmania pigra (Shuizhi/leech), Ligusticum chuanxiong (Chuanxiong), Angelica sinensis (Danggui), Carthamus tinctorius (Honghua/safflower), Prunus persica seed (Taoren/peach kernel), Paeonia veitchii root (Chishao/red peony root), Aucklandia lappa root (Muxiang/costus root), Acorus tatarinowii rhizome (Shichangpu/sweet flag rhizome), Pheretima aspergillum earthworm extract (Dilong/earthworm extract), Taxillus chinensis stem with leafs parasitic on mulberry tree branchlets or leaves(Sangjisheng/mulberry mistletoe) and Acanthopanax senticosus extractum(Eleutherococcus senticosus)[7]. Pharmacological studies suggest that the capsule exerts neuroprotective effects in animal models of intracerebral hemorrhage by reducing brain injury and inflammation. Mechanistically, it downregulates pro-inflammatory cytokines such as interleukin-1β and tumor necrosis factor-alpha at both protein and mRNA levels[6][3], modulates long non-coding RNAs involved in neural injury response[3][6], inhibits nuclear factor kappa B signaling pathway activation[4], suppresses NLRP3 inflammasome expression[4], regulates oxidative stress responses, promotes angiogenesis via vascular endothelial growth factor A pathways, influences apoptosis-related genes/proteins such as MMP9/NOS3/L6/TNF/CCL2/VEGFA through multi-target actions involving AGE-RAGE/HIF-1/Apelin signaling pathways[5]. The product is widely used clinically in China for treating ischemic stroke recovery phase with evidence also supporting its use in atherosclerosis management.

Brand names
Zhilong Huoxue Tongyu Capsule
Other names
蛭龙活血通瘀胶囊
02

Targets

NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)TNFA (Tumor necrosis factor alpha (soluble))RELA (Nuclear Factor Kappa B Subunit p65)IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on zhilong huoxue tongyu capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on zhilong huoxue tongyu capsule.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call